Bank of New York Mellon’s Global Blood Therapeutics, Inc. GBT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-272,788
| Closed | -$18.6M | – | 4636 |
|
|
2022
Q3 | $18.6M | Buy |
272,788
+18,594
| +7% | +$1.03M | ﹤0.01% | 1541 |
|
|
2022
Q2 | $8.12M | Sell |
254,194
-18,409
| -7% | -$539K | ﹤0.01% | 2061 |
|
|
2022
Q1 | $9.44M | Buy |
272,603
+876
| +0.3% | +$26.2K | ﹤0.01% | 2094 |
|
|
2021
Q4 | $7.95M | Sell |
271,727
-324
| -0.1% | -$10K | ﹤0.01% | 2227 |
|
|
2021
Q3 | $6.93M | Buy |
272,051
+6,548
| +2% | +$192K | ﹤0.01% | 2327 |
|
|
2021
Q2 | $9.3M | Buy |
265,503
+42,662
| +19% | +$1.67M | ﹤0.01% | 2180 |
|
|
2021
Q1 | $9.08M | Sell |
222,841
-6,480
| -3% | -$298K | ﹤0.01% | 2139 |
|
|
2020
Q4 | $9.93M | Sell |
229,321
-12,422
| -5% | -$612K | ﹤0.01% | 2005 |
|
|
2020
Q3 | $13.3M | Buy |
241,743
+8,957
| +4% | +$569K | ﹤0.01% | 1701 |
|
|
2020
Q2 | $14.7M | Sell |
232,786
-49,461
| -18% | -$3.39M | ﹤0.01% | 1627 |
|
|
2020
Q1 | $14.4M | Sell |
282,247
-22,070
| -7% | -$1.48M | ﹤0.01% | 1495 |
|
|
2019
Q4 | $24.2M | Sell |
304,317
-230,145
| -43% | -$13.6M | 0.01% | 1455 |
|
|
2019
Q3 | $25.9M | Buy |
534,462
+1,994
| +0.4% | +$104K | 0.01% | 1372 |
|
|
2019
Q2 | $28M | Sell |
532,468
-54,104
| -9% | -$3.11M | 0.01% | 1339 |
|
|
2019
Q1 | $31M | Buy |
586,572
+62,501
| +12% | +$3.07M | 0.01% | 1279 |
|
|
2018
Q4 | $21.5M | Buy |
524,071
+288,530
| +122% | +$10.8M | 0.01% | 1429 |
|
|
2018
Q3 | $8.95M | Sell |
235,541
-930
| -0.4% | -$41.2K | ﹤0.01% | 2082 |
|
|
2018
Q2 | $10.7M | Buy |
236,471
+15,211
| +7% | +$693K | ﹤0.01% | 1984 |
|
|
2018
Q1 | $10.7M | Buy |
221,260
+23,059
| +12% | +$1.29M | ﹤0.01% | 1946 |
|
|
2017
Q4 | $7.8M | Buy |
198,201
+9,319
| +5% | +$348K | ﹤0.01% | 2110 |
|
|
2017
Q3 | $5.87M | Buy |
188,882
+4,709
| +3% | +$132K | ﹤0.01% | 2268 |
|
|
2017
Q2 | $5.04M | Buy |
184,173
+44,784
| +32% | +$1.33M | ﹤0.01% | 2331 |
|
|
2017
Q1 | $5.14M | Buy |
139,389
+61,593
| +79% | +$1.55M | ﹤0.01% | 2314 |
|
|
2016
Q4 | $1.12M | Buy |
77,796
+6,521
| +9% | +$115K | ﹤0.01% | 3197 |
|
|
2016
Q3 | $1.64M | Buy |
71,275
+28,375
| +66% | +$541K | ﹤0.01% | 2884 |
|
|
2016
Q2 | $712K | Buy |
42,900
+12,940
| +43% | +$261K | ﹤0.01% | 3357 |
|
|
2016
Q1 | $475K | Buy |
29,960
+5
| +0% | +$89 | ﹤0.01% | 3461 |
|
|
2015
Q4 | $969K | Buy |
29,955
+13,770
| +85% | +$596K | ﹤0.01% | 3187 |
|
|
2015
Q3 | $683K | Buy |
+16,185
| New | +$764K | ﹤0.01% | 3413 |
|
Other funds holding GBT
Bank of New York Mellon's GBT Position: Q4 2022 in Review
Bank of New York Mellon sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 272,788 shares — an estimated $18.6M sold.
Bank of New York Mellon first reported a position in GBT in Q3 2015 and held it in 29 quarters. The position peaked at $31M in Q1 2019. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.
- Bank of New York Mellon reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
- Bank of New York Mellon sold 272,788 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $18.6M.
- Bank of New York Mellon first reported a position in Global Blood Therapeutics, Inc. in Q3 2015 and held it in 29 quarters.
- Bank of New York Mellon's Global Blood Therapeutics, Inc. position peaked at $31M in Q1 2019.
- 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.
Based on Bank of New York Mellon's 13F filing for Q4 2022, filed 14 Feb 2023.